Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Tax ProvisionsTax Rate
Others
Ratios

Lexaria Bioscience (LEXX) Consolidated Net Income (2017 - 2025)

Historic Consolidated Net Income for Lexaria Bioscience (LEXX) over the last 12 years, with Q4 2025 value amounting to -$1.6 million.

  • Lexaria Bioscience's Consolidated Net Income rose 4144.97% to -$1.6 million in Q4 2025 from the same period last year, while for Nov 2025 it was -$10.8 million, marking a year-over-year decrease of 4747.72%. This contributed to the annual value of -$11.9 million for FY2025, which is 10697.15% down from last year.
  • According to the latest figures from Q4 2025, Lexaria Bioscience's Consolidated Net Income is -$1.6 million, which was up 4144.97% from -$2.7 million recorded in Q3 2025.
  • Over the past 5 years, Lexaria Bioscience's Consolidated Net Income peaked at -$25000.0 during Q1 2021, and registered a low of -$3.8 million during Q2 2025.
  • Its 5-year average for Consolidated Net Income is -$1.8 million, with a median of -$1.7 million in 2022.
  • Per our database at Business Quant, Lexaria Bioscience's Consolidated Net Income tumbled by 6688273.33% in 2021 and then surged by 4953.21% in 2024.
  • Over the past 5 years, Lexaria Bioscience's Consolidated Net Income (Quarter) stood at -$2.0 million in 2021, then grew by 15.38% to -$1.7 million in 2022, then surged by 33.24% to -$1.1 million in 2023, then crashed by 137.73% to -$2.7 million in 2024, then surged by 41.45% to -$1.6 million in 2025.
  • Its Consolidated Net Income stands at -$1.6 million for Q4 2025, versus -$2.7 million for Q3 2025 and -$3.8 million for Q2 2025.